Document Detail

Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
MedLine Citation:
PMID:  22222314     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Alterations in the circadian arterial pressure rhythm predict cardiovascular mortality. We examined the circadian arterial pressure rhythm and the effect of renin-angiotensin system blockade in congenic mRen2.Lewis hypertensive rats, a renin-dependent model of hypertension derived from the backcross of transgenic hypertensive [mRen-2]27 rats with Lewis normotensive ones.
METHODS: Twenty-nine mRen2.Lewis hypertensive rats were randomly assigned to drink tap water (vehicle; n = 9), valsartan (30 mg/kg/day; n = 10), or valsartan (30 mg/kg/day) combined with aliskiren given subcutaneously (50 mg/kg/day; n = 10) for 2 weeks. Arterial pressure, heart rate, and locomotive activity were recorded with chronically implanted radiotelemetry probes. The awake/asleep ratio was calculated as [awake mean arterial pressure (MAP) mean - asleep MAP mean)] / (awake MAP mean) x 100. Plasma renin activity (PRA) and concentration (PRC), and plasma and kidney angiotensin II (Ang II) were measured by radioimmunoassay (RIAs).
RESULTS: Untreated hypertensive rats showed an inverse arterial pressure rhythm, higher at day and lower at night, accompanied by normal rhythms of heart rate and locomotive activity. Treatment with valsartan or aliskiren and valsartan normalized the elevated arterial pressure and the arterial pressure rhythm, with the combination therapy being more effective in reducing MAP and in restoring the awake/asleep ratio. While PRA and PRC increased with the treatments, the addition of aliskiren to valsartan partially reversed the increases in plasma Ang II levels. Valsartan and the aliskiren and valsartan combination markedly reduced the renal cortical content of Ang II.
CONCLUSION: The altered circadian arterial pressure rhythm in this renin-dependent hypertension model uncovers a significant role of Ang II in the desynchronization of the circadian rhythm of arterial pressure, heart rate, and locomotive activity.
Norihito Moniwa; Jasmina Varagic; Sarfaraz Ahmad; Jessica L VonCannon; Carlos M Ferrario
Related Documents :
25372284 - Invasibility of mediterranean-climate rivers by non-native fish: the importance of envi...
541054 - Serum immunoglobulins in hypertension.
1924654 - Cardiovascular reactivity to stress in black male offspring of hypertensive parents.
7375874 - Management of hypertension and changes in blood pressure level in patients included in ...
18406804 - The role of angiotensin-converting enzyme in blood pressure control, renal function, an...
937474 - The lacrimal drainage system: pressure changes in the canaliculus.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-01-05
Journal Detail:
Title:  Therapeutic advances in cardiovascular disease     Volume:  6     ISSN:  1753-9455     ISO Abbreviation:  Ther Adv Cardiovasc Dis     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-06     Completed Date:  2012-05-25     Revised Date:  2013-10-22    
Medline Journal Info:
Nlm Unique ID:  101316343     Medline TA:  Ther Adv Cardiovasc Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  15-29     Citation Subset:  IM    
Division of Surgical Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amides / administration & dosage,  pharmacology*
Angiotensin II Type 1 Receptor Blockers / pharmacology
Antihypertensive Agents / administration & dosage,  pharmacology*
Blood Pressure / drug effects
Circadian Rhythm
Disease Models, Animal
Drug Therapy, Combination
Fumarates / administration & dosage,  pharmacology*
Heart Rate / drug effects
Motor Activity / drug effects
Random Allocation
Rats, Inbred Lew
Rats, Transgenic
Receptors, Angiotensin / drug effects*,  metabolism
Renin / antagonists & inhibitors,  metabolism
Tetrazoles / administration & dosage,  pharmacology*
Valine / administration & dosage,  analogs & derivatives*,  pharmacology
Grant Support
Reg. No./Substance:
0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Fumarates; 0/Receptors, Angiotensin; 0/Tetrazoles; 137862-53-4/valsartan; 502FWN4Q32/aliskiren; 7004-03-7/Valine; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A practical strategy to create near-infrared luminescent probes: conversion from fluorescein-based s...
Next Document:  Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.